Treatment of jak2-mediated conditions

Provided is a method for treating a patient with anaemia, comprising the administration of N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide (CYT387 or momelotinib) or a related pyrimidine containing compound of the general formula (1) where the variables are defined in the specification. An example of a related compound is 4-(5-bromo-2-((4-morpholinophenyl)amino)pyrimidin-4-yl)-N-(cyanomethyl)benzamide. Further provided are an article of manufacture and a kit comprising CYT387 with a label or instructions related to the use of CYT387 in anaemia. Provided is an improved method for treating a subject having, or at risk of, a medical condition for which a JAK inhibitor is indicated, the method comprising selecting a subject that meets at least one of a number of criteria and administering CYT387 whereby the treated subject exhibits an anaemia and/or a spleen response that is improved relative to a subject not meeting any of the criteria. Further provided are an article of manufacture and a kit comprising CYT387 and a label or instructions related to the use of CYT387 in relation to the criteria of the improved method.